Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 19/20 | 0.87 |
| ▸ | INSR | P06213 | 16/20 | 0.87 |
| ▸ | IGF1R | P08069 | 16/20 | 0.87 |
| ▸ | EGFR | P00533 | 2/20 | 0.85 |
| ▸ | AURKA | O14965 | 2/20 | 0.85 |
| ▸ | ROS1 | P08922 | 2/20 | 0.85 |
| ▸ | EML4 | Q9HC35 | 2/20 | 0.85 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.85 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.85 |
| ▸ | JAK2 | O60674 | 1/20 | 0.85 |
| ▸ | STK10 | O94804 | 1/20 | 0.85 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.85 |
| ▸ | SLC34A2 | O95436 | 1/20 | 0.85 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.85 |
| ▸ | ABL1 | P00519 | 1/20 | 0.85 |
| ▸ | CD74 | P04233 | 1/20 | 0.85 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.85 |
| ▸ | LCK | P06239 | 1/20 | 0.85 |
| ▸ | FYN | P06241 | 1/20 | 0.85 |
| ▸ | FES | P07332 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30090724 | 1.00 | ALK (0.87) | ALKINSRIGF1REGFRAURKA | |
| SCHEMBL11916541 | 0.94 | ALK (0.93) | ALKINSRIGF1REGFRAURKA | |
| SCHEMBL24817950 | 0.93 | ALK (0.76) | ALKINSRIGF1REGFRAURKA | |
| SCHEMBL11916537 | 0.93 | INSR (1.00) | ALKINSRIGF1REGFRAURKA | |
| SCHEMBL11916456 | 0.93 | ALK (0.85) | ALKINSRIGF1REGFRAURKA | |
| SCHEMBL30180253 | 0.93 | ALK (0.85) | ALKINSRIGF1REGFRAURKA | |
| SCHEMBL11916520 | 0.92 | INSR (0.98) | ALKINSRIGF1REGFRAURKA | |
| SCHEMBL15217786 | 0.92 | INSR (0.88) | ALKINSRIGF1REGFRAURKA | |
| Brigatinib SCHEMBL11916361 | 0.92 | ALK (1.00) | ALKINSRIGF1REGFRAURKA | |
| Brigatinib SCHEMBL29350096 | 0.92 | ALK (1.00) | ALKINSRIGF1REGFRAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3725771-B1 | ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF | UNIV SHANGHAI TECHNOLOGY (CN) | 2026-02-04 | — | — | EP | disclosed |
| WO-2024059525-A2 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANAPLASTIC LYMPHOMA KINASE AND ROS1 KINASE | ENDOTARGET, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| CN-116940581-A | Novel protein degradation agent and application thereof | 和径医药科技（上海）有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-11771709-B2 | ALK protein degradation agent and anti-tumor application thereof | SHANGHAITECH UNIVERSITY (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11771709-B2 | ALK protein degradation agent and anti-tumor application thereof | SHANGHAITECH UNIVERSITY (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11771709-B2 | ALK protein degradation agent and anti-tumor application thereof | SHANGHAITECH UNIVERSITY (CN) | 2023-10-03 | — | — | US | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| CN-116323580-A | Conjugated degradation (EGFR) of EGFR inhibitors to E3 ligase ligands and methods of use | 百济神州有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-116239566-A | E3 ubiquitin ligase ligand compound, protein degradation agent developed based on ligand compound and application thereof | 标新生物医药科技(上海)有限公司 | 2023-06-09 | — | — | CN | disclosed |
| EP-4019021-A1 | COMPOUND INHIBITING AND INDUCING DEGRADATION OF EGFR AND ALK | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2022-06-29 | — | — | EP | disclosed |
| US-9012462-B2 | Phosphorous derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-9012462-B2 | Phosphorous derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | ALK 220/4885INSR 1023/4885IGF1R 115/4885 |
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | ALK 316/4885INSR 767/4885IGF1R 543/4885 |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | PHKA1, PIK3CA, PHKA2 | ALK 370/4885INSR 751/4885IGF1R 477/4885 |
| US-11771709-B2 | ALK protein degradation agent and anti-tumor application thereof | ADRM1, VHL, MDM2 | ALK 5/4885INSR 1929/4885IGF1R 306/4885 |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | ALK 316/4885INSR 767/4885IGF1R 543/4885 |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | ALK 316/4885INSR 767/4885IGF1R 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.